Pharma Reaserch Prod Co Ltd

Pharma Reaserch Prod Co Ltd

214450 · KQ · Healthcare / Biotechnology

251,000.00KRW+3500.00 (+1.41%)

Price History

Full chart

Market Stats

Previous Close247,500.00
Open247,500.00
Day Range245,000.00 – 253,500.00
52-Week Range208,000.00 – 561,000.00
Volume72.77K
Market Cap2.20T
P/E (TTM)12.45
Forward P/E0.00
EPS17,872.55
Dividend Yield1.75%
Beta0.47
50-Day Avg327,170.00
200-Day Avg337,842.50

About

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Sang-Soo Jung
  • Employees549
  • Headquarters77-19, Gwahakdanji-ro, Gangneung-si, South Korea, 25452, Korea
  • Websitehttps://pharmaresearch.co.kr

Leadership

  • Mr. Sang-Soo JungChief Executive Officer · b. 1958

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue37.45B45.95B54.47B64.28B83.87B108.75B154.08B194.76B261.01B350.12B536.29B
Growth (%)-+22.69%+18.53%+18.01%+30.48%+29.66%+41.69%+26.40%+34.02%+34.14%+53.18%
Cost of Revenue11.69B15.12B18.40B26.06B33.77B35.85B45.75B53.25B70.75B98.88B125.07B
Gross Profit25.77B30.84B36.06B38.22B50.11B72.90B108.33B141.51B190.26B251.24B411.22B
Gross Margin68.80%67.11%66.21%59.45%59.74%67.03%70.31%72.66%72.89%71.76%76.68%
Operating Expense9.68B16.73B22.10B30.38B31.04B40.72B56.68B80.71B101.12B125.64B196.82B
Operating Income16.09B14.11B13.96B7.84B19.06B32.17B51.65B60.80B89.14B125.60B214.40B
Operating Margin42.96%30.69%25.63%12.19%22.73%29.59%33.52%31.22%34.15%35.87%39.98%
EBITDA-------68.48B115.69B134.09B242.72B
EBITDA Margin-------35.16%44.32%38.30%45.26%
Net Income12.88B13.91B12.96B14.41B16.67B32.77B46.69B40.58B76.55B92.04B165.12B
Net Income Margin34.38%30.27%23.78%22.41%19.87%30.14%30.30%20.83%29.33%26.29%30.79%
R&D1.76B3.38B4.50B4.04B5.61B5.54B6.74B8.70B15.03B21.18B35.86B
R&D as % of Total Revenue4.71%7.35%8.26%6.29%6.69%5.10%4.37%4.47%5.76%6.05%6.69%
Interest Expense000001.79B1.31B3.83B2.99B4.63B10.39B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%1.64%0.85%1.97%1.14%1.32%1.94%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets169.31B179.33B189.03B258.19B269.93B319.83B427.65B478.06B535.28B855.70B1.04T
Total Liabilities12.56B7.69B10.18B60.56B60.85B74.41B122.20B134.55B73.09B286.26B320.01B
Total Equity156.75B171.64B178.85B197.62B209.07B245.42B305.44B343.50B433.10B539.40B689.33B
Cash14.86B17.63B16.98B21.10B19.74B26.71B2.96M8.10M67.24B165.35B175.66B
Total Debt5.40B--19.08B19.35B27.83B-----
Net Debt------19.80B----

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow16.02B8.16B8.56B5.20B19.27B32.39B65.30B59.40B64.95B139.88B183.16B
Investing Cash Flow-119.11B-1.02B-2.97B-18.38B-11.64B-36.21B-93.75B-11.91B-44.67B-225.54B-
Financing Cash Flow108.07B-4.58B-5.70B16.92B-9.10B11.09B42.97B-9.30B-25.97B182.64B-
Capital Expenditure462.99M1.96B7.63B28.60B9.59B34.78B20.64B17.76B13.20B38.73B35.78B
Free Cash Flow------2.99B41.51B41.65B51.75B99.40B147.38B
Dividends Paid1.89B1.89B2.82B2.80B2.97B2.96B5.03B6.32B7.53B10.09B11.73B
FCF to OCF------9.23%63.57%70.11%79.68%71.06%80.46%
Dividend Paid to FCF------99.11%12.12%15.16%14.55%10.15%7.96%

Earnings

Report DateOct 21, 2015Feb 3, 2016May 9, 2016Aug 11, 2016Nov 14, 2016Mar 18, 2017May 15, 2017Aug 10, 2017Nov 14, 2017Mar 9, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Feb 26, 2019May 15, 2019Aug 14, 2019Nov 13, 2019Feb 17, 2020May 13, 2020Aug 13, 2020Nov 11, 2020Jan 31, 2021May 14, 2021Aug 16, 2021Nov 11, 2021Feb 9, 2022May 13, 2022Aug 15, 2022Nov 13, 2022Feb 15, 2023May 15, 2023Aug 11, 2023Nov 14, 2023Mar 15, 2024May 14, 2024Aug 7, 2024Nov 12, 2024Mar 13, 2025May 13, 2025Aug 8, 2025Nov 11, 2025Mar 19, 2026May 15, 2026Aug 14, 2026
EPS Estimate-------------------572.17630.49697.33--697.33697.331238.991223.661243.831479.881358.471799.352088.032483.002231.122336.23----3697.193686.323557.034043.92
EPS Actual565.25304.00438.59492.36455.5184.58488.96402.13574.07-82.60445.84244.35121.00702.00536.00359.00403.88459.04516.001045.00807.001079.001268.381149.001332.00970.38934.001011.001721.00423.001765.001625.002583.001523.001682.002506.161859.70968.263287.104098.854234.393051.004245.004892.00
Surprise-------------------82.64%28.00%54.73%--91.01%39.16%-24.62%-17.38%38.36%-71.42%29.93%-9.69%23.71%-38.66%-24.61%7.27%----14.53%-17.23%19.34%20.97%
TimingPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-market-After-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-Pre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap2.20T
Enterprise Value1.62T
Trailing P/E12.45
Forward P/E0.00
Price / Sales3.65
Price / Book2.92
EPS17,872.55
Book Value72,540.68
Revenue (TTM)603.58B
Gross Profit (TTM)469.05B
EBITDA252.62B
Profit Margin30.77%
Operating Margin37.23%
Return on Equity27.34%
Return on Assets14.52%
Shares Outstanding10.39M
Shares Float5.57M
Beta0.47
Dividend Yield1.75%
Dividend Rate3,700.00
Payout Ratio30.36%

Dividends

20251×
3700.00Dec 29, 2025
20241×
1100.00Dec 27, 2024
20231×
950.00Dec 27, 2023
20221×
660.00Dec 28, 2022
20211×
600.00Dec 29, 2021
20201×
500.00Dec 29, 2020
20191×
300.00Dec 27, 2019
20181×
300.00Dec 27, 2018
20171×
300.00Dec 27, 2017
20161×
300.00Dec 28, 2016
20151×
200.00Dec 29, 2015